Novo Nordisk A/S (NYSE:NVO) has delivered encouraging late-stage data for Wegovy in younger children, with its STEP Young trial showing that 40.4% of children aged 6 to under 12 were no longer classified as having obesity after 68 weeks of semaglutide treatment, compared with none in the placebo group. The trial met its primary endpoint, showing a greater reduction in BMI versus placebo. Importantly, both groups also followed a reduced-calorie diet and increased physical activity.
The results are particularly notable because more than 85% of participants had severe class II or III obesity at the start of the study. Novo said the drug’s safety and tolerability were consistent with previous semaglutide trials in adults and adolescents.
Strong Trial Results Open Another Door for Novo’s Obesity Franchise
The results could open another significant growth opportunity for Wegovy. Novo Nordisk A/S is already facing pressure to sustain growth from its obesity franchise, so expanding semaglutide into a younger patient population could extend the commercial runway of one of its most important drugs. Bloomberg noted that this is the first trial examining Wegovy’s effect specifically in young children, while Eli Lilly has yet to demonstrate similar results in this age group.
The 40.4% response rate is particularly encouraging because the treatment was tested in children with substantial levels of obesity, rather than a relatively healthy population. The fact that none of the placebo patients crossed below the obesity threshold also provides a strong contrast between semaglutide and lifestyle intervention alone. The results could also strengthen Novo Nordisk A/S’s position in the broader pediatric obesity market. Reuters reported that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 have increased more than 300-fold since 2019, despite these drugs not yet being approved for that age group. That suggests there is already meaningful demand for medical treatment in this population.
From an investor perspective, the biggest positive is the validation of semaglutide beyond the adult market. If regulators ultimately approve the treatment for younger children, Novo could gain access to patients earlier in the obesity disease cycle, potentially creating a longer duration of treatment and a broader addressable market.
A Promising Trial May Not Translate Into Near-Term Revenue Growth
The trial does not immediately translate into a new revenue stream. Regulatory approval will still be required before Wegovy can be broadly marketed for children in this age group. Moreover, treating young children for obesity raises particularly important questions around long-term safety, growth, development, and how long patients would need to remain on therapy.
The trial itself was also relatively small, involving 165 children, and the main reported results cover 68 weeks. Novo’s study is scheduled to evaluate additional outcomes through week 104, meaning investors still have to wait for longer-term data.
Another consideration is that the 40.4% figure assumes adherence to treatment. The headline result therefore represents the treatment effect if children remain on therapy, rather than necessarily reflecting what will happen across a real-world population where adherence, discontinuation and access can be less consistent. Reuters specifically noted this distinction.
There is also a broader concern that Novo is becoming increasingly dependent on its obesity franchise. The company recently halted two additional cardiovascular trials for ziltivekimab after an earlier late-stage failure, further weakening its efforts to diversify beyond obesity and diabetes. Meanwhile, Novo continues to face competitive pressure from Eli Lilly in the obesity market. Bloomberg noted that Novo’s shares have already been under pressure as investors look for renewed growth.
Conclusion
The STEP Young results are clearly positive for Novo Nordisk A/S, but they are more of a long-term growth catalyst than an immediate earnings driver. Showing that semaglutide helped 40.4% of severely obese children move below the obesity threshold gives Novo a strong clinical foundation for potentially expanding Wegovy into the 6-to-under-12 population. It also strengthens the company’s competitive position against rival obesity-drug makers in an area where demand is already emerging.
However, the investment case still depends on regulatory approval, longer-term pediatric safety data, and sustained treatment adherence. At the same time, Novo’s recent setbacks outside obesity highlight why investors remain focused on whether the company can build growth beyond its existing GLP-1 franchise. Overall, the news tilts bullish for Novo Nordisk: it reinforces the durability and breadth of the Wegovy franchise, but the commercial impact is likely to materialize gradually rather than immediately.
READ NEXT: Illumina and Everpure to Join S&P 500 in September Rebalancing: What it Means for Investors and Citigroup (C) Moves Deeper Into China’s Capital Markets as Competition Intensifies
This article is originally published at Insider Monkey.
